Annual SGA
$6.72 M
-$664.00 K-8.99%
December 31, 2023
Summary
- As of March 7, 2025, CYCC annual SGA is $6.72 million, with the most recent change of -$664.00 thousand (-8.99%) on December 31, 2023.
- During the last 3 years, CYCC annual SGA has risen by +$841.00 thousand (+14.31%).
- CYCC annual SGA is now -99.72% below its all-time high of $2.42 billion, reached on January 1, 1993.
Performance
CYCC SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$1.24 M
-$388.00 K-23.88%
September 30, 2024
Summary
- As of March 7, 2025, CYCC quarterly SGA is $1.24 million, with the most recent change of -$388.00 thousand (-23.88%) on September 30, 2024.
- Over the past year, CYCC quarterly SGA has dropped by -$636.00 thousand (-33.96%).
- CYCC quarterly SGA is now -69.86% below its all-time high of $4.10 million, reached on June 30, 2008.
Performance
CYCC Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.73 B
-$13.43 M-0.78%
September 30, 2024
Summary
- As of March 7, 2025, CYCC TTM SGA is -$1.73 billion, with the most recent change of -$13.43 million (-0.78%) on September 30, 2024.
- Over the past year, CYCC TTM SGA has dropped by -$1.74 billion (-25858.22%).
- CYCC TTM SGA is now -1898.31% below its all-time high of -$86.59 million.
Performance
CYCC TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
CYCC Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.0% | -34.0% | -10000.0% |
| 3 y3 years | +14.3% | -24.8% | -10000.0% |
| 5 y5 years | +25.1% | -24.8% | -10000.0% |
CYCC Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -10.0% | at low | -42.3% | at low | -14.7% | at low |
| 5 y | 5-year | -10.0% | +33.7% | -42.3% | at low | -22.0% | at low |
| alltime | all time | -99.7% | +179.6% | -69.9% | +69.5% | -1898.3% | at low |
Cyclacel Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.24 M(-23.9%) | $6.32 M(-5.8%) |
| Jun 2024 | - | $1.63 M(+2.7%) | $6.71 M(+0.8%) |
| Mar 2024 | - | $1.58 M(-15.5%) | $6.66 M(-0.9%) |
| Dec 2023 | $6.72 M(-9.0%) | $1.87 M(+15.3%) | $6.72 M(-3.9%) |
| Sep 2023 | - | $1.63 M(+3.2%) | $6.99 M(-5.8%) |
| Jun 2023 | - | $1.57 M(-4.3%) | $7.42 M(-0.1%) |
| Mar 2023 | - | $1.65 M(-23.2%) | $7.42 M(+0.5%) |
| Dec 2022 | $7.38 M(-1.1%) | $2.14 M(+4.3%) | $7.38 M(+2.8%) |
| Sep 2022 | - | $2.05 M(+30.0%) | $7.18 M(+4.0%) |
| Jun 2022 | - | $1.58 M(-1.6%) | $6.91 M(-5.7%) |
| Mar 2022 | - | $1.60 M(-17.3%) | $7.33 M(-1.8%) |
| Dec 2021 | $7.46 M(+27.0%) | $1.94 M(+9.0%) | $7.46 M(+2.6%) |
| Sep 2021 | - | $1.78 M(-10.9%) | $7.27 M(+4.1%) |
| Jun 2021 | - | $2.00 M(+15.0%) | $6.99 M(+11.0%) |
| Mar 2021 | - | $1.74 M(-0.8%) | $6.30 M(+7.2%) |
| Dec 2020 | $5.88 M(+17.0%) | $1.75 M(+17.1%) | $5.88 M(+7.1%) |
| Sep 2020 | - | $1.50 M(+14.4%) | $5.49 M(+4.0%) |
| Jun 2020 | - | $1.31 M(-0.7%) | $5.28 M(+2.4%) |
| Mar 2020 | - | $1.32 M(-3.3%) | $5.15 M(+2.5%) |
| Dec 2019 | $5.02 M(-6.5%) | $1.36 M(+6.1%) | $5.02 M(-2.1%) |
| Sep 2019 | - | $1.28 M(+8.5%) | $5.13 M(+0.7%) |
| Jun 2019 | - | $1.18 M(-0.7%) | $5.10 M(-1.9%) |
| Mar 2019 | - | $1.19 M(-19.1%) | $5.20 M(-3.2%) |
| Dec 2018 | $5.37 M(+2.2%) | $1.47 M(+17.8%) | $5.37 M(+0.4%) |
| Sep 2018 | - | $1.25 M(-2.6%) | $5.35 M(+1.8%) |
| Jun 2018 | - | $1.28 M(-5.9%) | $5.25 M(+0.3%) |
| Mar 2018 | - | $1.36 M(-6.1%) | $5.24 M(-0.3%) |
| Dec 2017 | $5.25 M(-4.7%) | $1.45 M(+25.8%) | $5.25 M(-1.2%) |
| Sep 2017 | - | $1.15 M(-8.9%) | $5.32 M(-2.2%) |
| Jun 2017 | - | $1.27 M(-8.3%) | $5.43 M(-1.4%) |
| Mar 2017 | - | $1.38 M(-8.8%) | $5.51 M(-0.1%) |
| Dec 2016 | $5.52 M(-3.8%) | $1.51 M(+18.9%) | $5.52 M(-3.7%) |
| Sep 2016 | - | $1.27 M(-5.4%) | $5.73 M(+1.2%) |
| Jun 2016 | - | $1.34 M(-2.8%) | $5.66 M(+0.2%) |
| Mar 2016 | - | $1.38 M(-19.8%) | $5.65 M(-1.5%) |
| Dec 2015 | $5.73 M(-2.7%) | $1.73 M(+43.2%) | $5.73 M(+2.0%) |
| Sep 2015 | - | $1.21 M(-9.6%) | $5.62 M(-3.9%) |
| Jun 2015 | - | $1.33 M(-9.2%) | $5.85 M(-0.9%) |
| Mar 2015 | - | $1.47 M(-9.0%) | $5.90 M(+0.1%) |
| Dec 2014 | $5.89 M(-24.3%) | $1.61 M(+12.6%) | $5.89 M(-2.8%) |
| Sep 2014 | - | $1.43 M(+3.4%) | $6.06 M(-1.6%) |
| Jun 2014 | - | $1.39 M(-5.2%) | $6.16 M(-6.1%) |
| Mar 2014 | - | $1.46 M(-18.0%) | $6.56 M(-15.7%) |
| Dec 2013 | $7.78 M | $1.78 M(+16.5%) | $7.78 M(-10.2%) |
| Sep 2013 | - | $1.53 M(-14.4%) | $8.66 M(-5.4%) |
| Jun 2013 | - | $1.79 M(-33.4%) | $9.16 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | $2.68 M(+0.8%) | $9.49 M(+10.7%) |
| Dec 2012 | $8.58 M(+31.2%) | $2.66 M(+31.3%) | $8.58 M(+17.2%) |
| Sep 2012 | - | $2.03 M(-4.4%) | $7.32 M(+3.0%) |
| Jun 2012 | - | $2.12 M(+20.0%) | $7.11 M(+1.2%) |
| Mar 2012 | - | $1.77 M(+25.7%) | $7.02 M(-0.5%) |
| Dec 2011 | $6.54 M(-25.9%) | $1.41 M(-22.5%) | $7.06 M(+10.6%) |
| Sep 2011 | - | $1.81 M(-10.8%) | $6.38 M(-11.1%) |
| Jun 2011 | - | $2.03 M(+12.6%) | $7.18 M(-12.8%) |
| Mar 2011 | - | $1.81 M(+147.4%) | $8.24 M(-6.7%) |
| Dec 2010 | $8.83 M(+3.5%) | $730.00 K(-72.1%) | $8.84 M(-11.1%) |
| Sep 2010 | - | $2.61 M(-15.5%) | $9.94 M(+4.5%) |
| Jun 2010 | - | $3.09 M(+28.7%) | $9.52 M(+9.3%) |
| Mar 2010 | - | $2.40 M(+30.9%) | $8.71 M(+2.0%) |
| Dec 2009 | $8.54 M(-44.4%) | $1.83 M(-16.1%) | $8.54 M(-20.4%) |
| Sep 2009 | - | $2.19 M(-4.2%) | $10.72 M(-8.8%) |
| Jun 2009 | - | $2.29 M(+2.5%) | $11.75 M(-13.4%) |
| Mar 2009 | - | $2.23 M(-44.5%) | $13.57 M(-10.8%) |
| Dec 2008 | $15.35 M(+33.0%) | $4.02 M(+24.8%) | $15.22 M(+3.4%) |
| Sep 2008 | - | $3.22 M(-21.6%) | $14.72 M(+5.0%) |
| Jun 2008 | - | $4.10 M(+5.9%) | $14.03 M(+15.8%) |
| Mar 2008 | - | $3.88 M(+10.1%) | $12.11 M(+11.5%) |
| Dec 2007 | $11.54 M(-6.3%) | $3.52 M(+39.6%) | $10.86 M(+6.4%) |
| Sep 2007 | - | $2.52 M(+15.4%) | $10.21 M(+0.1%) |
| Jun 2007 | - | $2.19 M(-16.9%) | $10.19 M(-7.6%) |
| Mar 2007 | - | $2.63 M(-8.1%) | $11.04 M(-10.4%) |
| Dec 2006 | $12.32 M(+132.9%) | $2.86 M(+14.0%) | $12.32 M(+11.1%) |
| Sep 2006 | - | $2.51 M(-17.1%) | $11.09 M(+16.0%) |
| Jun 2006 | - | $3.03 M(-22.6%) | $9.56 M(+19.6%) |
| Mar 2006 | - | $3.92 M(+139.6%) | $8.00 M(+51.2%) |
| Dec 2005 | $5.29 M(-23.1%) | $1.63 M(+65.9%) | $5.29 M(-3.6%) |
| Sep 2005 | - | $985.00 K(-32.8%) | $5.49 M(-12.2%) |
| Jun 2005 | - | $1.47 M(+21.5%) | $6.25 M(-4.0%) |
| Mar 2005 | - | $1.21 M(-34.1%) | $6.51 M(-5.4%) |
| Dec 2004 | $6.88 M(+59.1%) | $1.83 M(+4.5%) | $6.88 M(+9.9%) |
| Sep 2004 | - | $1.75 M(+1.6%) | $6.26 M(+15.3%) |
| Jun 2004 | - | $1.72 M(+9.5%) | $5.42 M(+14.4%) |
| Mar 2004 | - | $1.57 M(+30.1%) | $4.74 M(+9.7%) |
| Dec 2003 | $4.32 M(-13.2%) | $1.21 M(+31.8%) | $4.32 M(+38.9%) |
| Sep 2003 | - | $918.00 K(-11.7%) | $3.11 M(+41.8%) |
| Jun 2003 | - | $1.04 M(-9.9%) | $2.19 M(+90.1%) |
| Mar 2003 | - | $1.15 M | $1.15 M |
| Dec 2002 | $4.98 M(-4.3%) | - | - |
| Dec 2001 | $5.20 M(+116.6%) | - | - |
| Dec 2000 | $2.40 M(-99.9%) | - | - |
| Jan 1994 | $2.32 B(-4.0%) | - | - |
| Jan 1993 | $2.42 B | - | - |
FAQ
- What is Cyclacel Pharmaceuticals annual SGA?
- What is the all time high annual SGA for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual SGA year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly SGA?
- What is the all time high quarterly SGA for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly SGA year-on-year change?
- What is Cyclacel Pharmaceuticals TTM SGA?
- What is the all time high TTM SGA for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals TTM SGA year-on-year change?
What is Cyclacel Pharmaceuticals annual SGA?
The current annual SGA of CYCC is $6.72 M
What is the all time high annual SGA for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual SGA is $2.42 B
What is Cyclacel Pharmaceuticals annual SGA year-on-year change?
Over the past year, CYCC annual SGA has changed by -$664.00 K (-8.99%)
What is Cyclacel Pharmaceuticals quarterly SGA?
The current quarterly SGA of CYCC is $1.24 M
What is the all time high quarterly SGA for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly SGA is $4.10 M
What is Cyclacel Pharmaceuticals quarterly SGA year-on-year change?
Over the past year, CYCC quarterly SGA has changed by -$636.00 K (-33.96%)
What is Cyclacel Pharmaceuticals TTM SGA?
The current TTM SGA of CYCC is -$1.73 B
What is the all time high TTM SGA for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high TTM SGA is -$86.59 M
What is Cyclacel Pharmaceuticals TTM SGA year-on-year change?
Over the past year, CYCC TTM SGA has changed by -$1.74 B (-25858.22%)